Company Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014.
Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2009 |
| IPO Date | Feb 13, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 United States | |
| Phone | 908-574-4770 |
| Website | bellerophon.com |
Stock Details
| Ticker Symbol | BLPH |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600132 |
| CUSIP Number | 078771300 |
| ISIN Number | US0787713009 |
| Employer ID | 47-3116175 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Treasurer, Secretary, Principal Executive, Financial and Accounting Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2024 | 15-12G | Securities registration termination |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | SCHEDULE 13G | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 30, 2024 | 8-K | Current Report |
| Jan 26, 2024 | SCHEDULE 13G | Filing |
| Jan 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |